Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14927315 | 1.00 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL8276850 | 1.00 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL25323472 | 0.90 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3805162 | 0.90 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL18618732 | 0.83 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL3747054 | 0.83 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL17977215 | 0.81 | ROCK2 (0.47) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL29282704 | 0.81 | KDM1A (0.45) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL4102268 | 0.81 | KDM1A (0.45) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL1262781 | 0.81 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4635958-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024201322-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | WO | disclosed |
| CN-115279368-B | Heteroaryl compounds | 维瓦斯治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230106583-A1 | HETEROARYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115279368-A | Heteroaryl compounds | 维瓦斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4061364-A1 | HETEROARYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2022-09-28 | — | — | EP | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-1863812-A4 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD (KR) | 2009-06-24 | — | — | EP | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
| EP-1863812-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
| US-6245761-B1 | NERVOUS SYSTEM, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-06-12 | — | — | US | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106583-A1 | HETEROARYL COMPOUNDS | YAP1, MYC, HRAS | PDE4A 3784/4885PDE4B 3758/4885PDE4C 3827/4885 |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | CSF1R, CSF3R, FAR1 | PDE4A 2068/4885PDE4B 1465/4885PDE4C 1877/4885 |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | DPP4, DPP7, DPP8 | PDE4A 87/4885PDE4B 86/4885PDE4C 136/4885 |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | PDE4A 4686/4885PDE4B 4683/4885PDE4C 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.